Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.